Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Matthew Philip Goetz, William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, William B. Farrar, Sharon H. Giordano, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O’Regan & 13 others Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Melinda L. Telli, John H. Ward, Jessica S. Young, Dorothy A. Shead, Rashmi Kumar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Original languageEnglish (US)
Pages (from-to)118-126
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Adjuvant Chemotherapy
Hormones
Guidelines
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Breast cancer, version 3.2018 featured updates to the NCCN guidelines. / Goetz, Matthew Philip; Gradishar, William J.; Anderson, Benjamin O.; Abraham, Jame; Aft, Rebecca; Allison, Kimberly H.; Blair, Sarah L.; Burstein, Harold J.; Dang, Chau; Elias, Anthony D.; Farrar, William B.; Giordano, Sharon H.; Goldstein, Lori J.; Isakoff, Steven J.; Lyons, Janice; Kelly Marcom, P.; Mayer, Ingrid A.; Moran, Meena S.; Mortimer, Joanne; O’Regan, Ruth M.; Patel, Sameer A.; Pierce, Lori J.; Reed, Elizabeth C.; Rugo, Hope S.; Sitapati, Amy; Smith, Karen Lisa; Smith, Mary Lou; Soliman, Hatem; Telli, Melinda L.; Ward, John H.; Young, Jessica S.; Shead, Dorothy A.; Kumar, Rashmi.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 17, No. 2, 01.02.2019, p. 118-126.

Research output: Contribution to journalArticle

Goetz, MP, Gradishar, WJ, Anderson, BO, Abraham, J, Aft, R, Allison, KH, Blair, SL, Burstein, HJ, Dang, C, Elias, AD, Farrar, WB, Giordano, SH, Goldstein, LJ, Isakoff, SJ, Lyons, J, Kelly Marcom, P, Mayer, IA, Moran, MS, Mortimer, J, O’Regan, RM, Patel, SA, Pierce, LJ, Reed, EC, Rugo, HS, Sitapati, A, Smith, KL, Smith, ML, Soliman, H, Telli, ML, Ward, JH, Young, JS, Shead, DA & Kumar, R 2019, 'Breast cancer, version 3.2018 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 2, pp. 118-126. https://doi.org/10.6004/jnccn.2019.0009
Goetz, Matthew Philip ; Gradishar, William J. ; Anderson, Benjamin O. ; Abraham, Jame ; Aft, Rebecca ; Allison, Kimberly H. ; Blair, Sarah L. ; Burstein, Harold J. ; Dang, Chau ; Elias, Anthony D. ; Farrar, William B. ; Giordano, Sharon H. ; Goldstein, Lori J. ; Isakoff, Steven J. ; Lyons, Janice ; Kelly Marcom, P. ; Mayer, Ingrid A. ; Moran, Meena S. ; Mortimer, Joanne ; O’Regan, Ruth M. ; Patel, Sameer A. ; Pierce, Lori J. ; Reed, Elizabeth C. ; Rugo, Hope S. ; Sitapati, Amy ; Smith, Karen Lisa ; Smith, Mary Lou ; Soliman, Hatem ; Telli, Melinda L. ; Ward, John H. ; Young, Jessica S. ; Shead, Dorothy A. ; Kumar, Rashmi. / Breast cancer, version 3.2018 featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2019 ; Vol. 17, No. 2. pp. 118-126.
@article{70d813e3853348fda6c59e5021506d5a,
title = "Breast cancer, version 3.2018 featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.",
author = "Goetz, {Matthew Philip} and Gradishar, {William J.} and Anderson, {Benjamin O.} and Jame Abraham and Rebecca Aft and Allison, {Kimberly H.} and Blair, {Sarah L.} and Burstein, {Harold J.} and Chau Dang and Elias, {Anthony D.} and Farrar, {William B.} and Giordano, {Sharon H.} and Goldstein, {Lori J.} and Isakoff, {Steven J.} and Janice Lyons and {Kelly Marcom}, P. and Mayer, {Ingrid A.} and Moran, {Meena S.} and Joanne Mortimer and O’Regan, {Ruth M.} and Patel, {Sameer A.} and Pierce, {Lori J.} and Reed, {Elizabeth C.} and Rugo, {Hope S.} and Amy Sitapati and Smith, {Karen Lisa} and Smith, {Mary Lou} and Hatem Soliman and Telli, {Melinda L.} and Ward, {John H.} and Young, {Jessica S.} and Shead, {Dorothy A.} and Rashmi Kumar",
year = "2019",
month = "2",
day = "1",
doi = "10.6004/jnccn.2019.0009",
language = "English (US)",
volume = "17",
pages = "118--126",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Breast cancer, version 3.2018 featured updates to the NCCN guidelines

AU - Goetz, Matthew Philip

AU - Gradishar, William J.

AU - Anderson, Benjamin O.

AU - Abraham, Jame

AU - Aft, Rebecca

AU - Allison, Kimberly H.

AU - Blair, Sarah L.

AU - Burstein, Harold J.

AU - Dang, Chau

AU - Elias, Anthony D.

AU - Farrar, William B.

AU - Giordano, Sharon H.

AU - Goldstein, Lori J.

AU - Isakoff, Steven J.

AU - Lyons, Janice

AU - Kelly Marcom, P.

AU - Mayer, Ingrid A.

AU - Moran, Meena S.

AU - Mortimer, Joanne

AU - O’Regan, Ruth M.

AU - Patel, Sameer A.

AU - Pierce, Lori J.

AU - Reed, Elizabeth C.

AU - Rugo, Hope S.

AU - Sitapati, Amy

AU - Smith, Karen Lisa

AU - Smith, Mary Lou

AU - Soliman, Hatem

AU - Telli, Melinda L.

AU - Ward, John H.

AU - Young, Jessica S.

AU - Shead, Dorothy A.

AU - Kumar, Rashmi

PY - 2019/2/1

Y1 - 2019/2/1

N2 - These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

AB - These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

UR - http://www.scopus.com/inward/record.url?scp=85061964738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061964738&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0009

DO - 10.6004/jnccn.2019.0009

M3 - Article

VL - 17

SP - 118

EP - 126

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 2

ER -